Active, not recruitingPhase 2NCT04055909
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
Inotremn = 35513 Nov 2019 to est. 9 May 2023
Shock, Septic
Nangibotide / Studies
Synthetic fragment · 12 amino acids
Nangibotide studies and research data
PepBank has 24 nangibotide studies with results. 21 of them gave nangibotide, with 140 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 140 results and 40 papers. Newer studies from Europe PMC
Results in people
36
26% of 140 results
Results in animals
88
63% of 140 results
Results in lab cells
16
11% of 140 results
From computer models
0
0% of 140 results
The molecule
Nangibotide identity
Identifiers, parent molecule, targets and development stage, from curated data.
Nangibotide is a synthetic twelve-residue peptide derived from TREM-like transcript-1 (TLT-1, TREML1). It inhibits TREM-1 pathway activation as a decoy. FDA records include LR12, LR-12 and MOTREM as synonyms. Preclinical LR12 can denote a species-specific ortholog. LR12 literature therefore needs peptide and TREM-1 context, with separate sequence assessment.
- Kind
- Synthetic fragment · 12 residues
- Identifiers
- ChEMBLCHEMBL4297793 (opens in a new tab)UNII59HD7BLX9H (opens in a new tab)CAS2014384-91-7
- Parent
- Fragment of Trem-like transcript 1 protein (TLT-1, TREML1)The phase 1 paper establishes TLT-1 derivation. UniProt identifies human TREML1 as Q86YW5. Exact coordinates remain unset during the sequence dispute.
- Development
- Phase 2InotremPublished trials and ClinicalTrials.gov establish phase 2 development by Inotrem. The sponsor announced agreement on the ACCURATE phase 3 design in January 2024. The registry intervention query returns four phase 1/2 studies and does not establish phase 3 initiation. Source (opens in a new tab)
Targets
| Target | Action | Evidence |
|---|---|---|
| Triggering receptor expressed on myeloid cells 1TREM1Q9NP99 (opens in a new tab) | Inhibitor | The phase 1 paper describes TREM-1 pathway inhibition. NCI describes sequestration of its ligand.Source (opens in a new tab) |
Sequence and structure
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence
Sequence not disclosed
The phase 1 formulation and FDA GSRS specify H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH2, with L-configured chiral residues. PubChem CID 165360157 instead encodes LQQEDAGEYGCM-NH2. FDA GSRS also reports an estimated formula inconsistent with its sequence. Complete sequence, formula, masses, SMILES, InChIKey and HELM remain unset because these sources disagree. The reported phase 1 molecular weight is 1342.5 g/mol. PubChem assigns the same rounded weight to its different sequence. No cyclic structure or intramolecular disulfide is specified for the administered monomer.
Parent: Trem-like transcript 1 protein (TLT-1, TREML1)
No sequence is listed for the parent, so no alignment is shown.The phase 1 paper establishes TLT-1 derivation. UniProt identifies human TREML1 as Q86YW5. Exact coordinates remain unset during the sequence dispute.
Properties
From identity sources
No formula or molecular weight is listed for Nangibotide.
Calculated from the sequence
No sequence is listed, so nothing can be calculated.
Net charge by pH
No charge curve
No sequence is listed for this peptide.
Composition
No sequence is listed for this peptide.
3D structure
PredictedAlphaFold DB · Q86YW5
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
Results by area
What the studies measured
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
Trials and papers
Newer studies
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Status and safety
Data